Tempus AI, Inc. (NASDAQ:TEM) Director Sells $25,922.20 in Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 620 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the transaction, the director now owns 27,894 shares of the company’s stock, valued at $1,166,248.14. This represents a 2.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Tempus AI Price Performance

TEM stock opened at $41.00 on Monday. The stock’s 50-day moving average is $52.64. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $79.49.

Institutional Trading of Tempus AI

A number of institutional investors and hedge funds have recently modified their holdings of the stock. First Horizon Advisors Inc. purchased a new stake in shares of Tempus AI during the third quarter worth about $30,000. Geode Capital Management LLC raised its holdings in Tempus AI by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after acquiring an additional 539 shares during the last quarter. Vestor Capital LLC purchased a new position in Tempus AI in the 3rd quarter worth approximately $153,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Tempus AI by 10.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock worth $1,686,000 after purchasing an additional 2,765 shares during the last quarter. Finally, Stifel Financial Corp purchased a new stake in shares of Tempus AI in the third quarter valued at approximately $218,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on TEM shares. Bank of America boosted their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday. Loop Capital upped their price objective on shares of Tempus AI from $48.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday, October 15th. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Guggenheim initiated coverage on shares of Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Finally, Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and upped their price objective for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $56.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.